Journal of Human Reproductive Science
Home Ahead of Print Current Issue Archives
   Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size    Users online: 517

   Table of Contents     
Year : 2014  |  Volume : 7  |  Issue : 2  |  Page : 93-98

Autologous stem cell transplantation in refractory Asherman's syndrome: A novel cell based therapy

Department of Obstetrics and Gynaecology and Stem Cell Facility, All India Institute of Medical Sciences, New Delhi, India

Date of Submission15-Jan-2014
Date of Decision26-Mar-2014
Date of Acceptance26-May-2014
Date of Web Publication16-Aug-2014

Correspondence Address:
Neeta Singh
Department of Obstetrics and Gynecology, Room No. 3090A, Third Floor, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029
Login to access the Email id

Source of Support: Research grant from All India Institute of Medical Sciences, Conflict of Interest: None

DOI: 10.4103/0974-1208.138864

Clinical trial registration CTRI/2013/08/003896.

Rights and Permissions



Background : There is substantial evidence that adult stem cell populations exist in human endometrium, and hence it is suggested that either endogenous endometrial stem/progenitor cells can be activated or bone marrow derived stem cells can be transplanted in the uterine cavity for endometrial regeneration in Asherman's syndrome (AS). Aims and Objectives : The objective was to evaluate the role of sub-endometrial autologous stem cell implantation in women with refractory AS in attaining menstruation and fertility. Setting : Tertiary care referral center. DESIGN: Prospective case series. Materials and Methods : Six cases of refractory AS with failed standard treatment option of hysteroscopic adhesiolysis in the past were included. Mononuclear stem cells (MNCs) were implanted in sub-endometrial zone followed by exogenous oral estrogen therapy. Endometrial thickness (ET) was assessed at 3, 6, and 9 months. RESULTS: Descriptive statistics and statistical analysis of study variables was carried out using STATA version 9.0. The mean MNC count was 103.3 × 106 (±20.45) with mean CD34+ count being 203,642 (±269,274). Mean of ET (mm) at 3 months (4.05 ± 1.40), 6 months (5.46 ± 1.36) and 9 months (5.48 ± 1.14) were significantly (P < 0.05) increased from pretreatment level (1.38 ± 0.39). Five out of six patients resumed menstruation. Conclusion : The autologous stem cell implantation leads to endometrial regeneration reflected by restoration of menstruation in five out of six cases. Autologous stem cell implantation is a promising novel cell based therapy for refractory AS.

Keywords: Asherman′s syndrome, autologous stem cells, bone marrow, endometrial regeneration

How to cite this article:
Singh N, Mohanty S, Seth T, Shankar M, Bhaskaran S, Dharmendra S. Autologous stem cell transplantation in refractory Asherman's syndrome: A novel cell based therapy. J Hum Reprod Sci 2014;7:93-8

How to cite this URL:
Singh N, Mohanty S, Seth T, Shankar M, Bhaskaran S, Dharmendra S. Autologous stem cell transplantation in refractory Asherman's syndrome: A novel cell based therapy. J Hum Reprod Sci [serial online] 2014 [cited 2022 Jul 5];7:93-8. Available from:

   Introduction Top

Asherman's syndrome (AS) is the partial or complete obliteration of the uterine cavity and or cervical canal with synechiae, resulting in menstrual abnormalities hypomenorrhea, amenorrhea, infertility and recurrent pregnancy loss, depending on the severity. The prevalence of AS varies according to the population studied and the investigations used for its detection. [1] It's prevalence varies from 2% to 22% in infertile women. [2],[3] The main etiology includes trauma to gravid (postpartum curettage - 21.5-40%) [4],[5],[6] and nongravid uterine cavity (diagnostic curettage - 1.6%, abdominal myomectomy - 1.3%, intrauterine contraceptive device [IUCD] insertion - 0.2%), [1] miscarriages (5-39%), [7],[8],[9],[10],[11] infections particularly genital tuberculosis (TB), schistosomiasis and genetic predisposition. Endometrial regeneration from the basal layer, postulated to have stem cells or progenitor cells, contributes to the replacement of the functional layer. The basal layer concomitant with the stem cells/progenitor cells of the endometrium, are often removed or destroyed during these conditions. The endometrial stroma is largely replaced by fibrous tissue and the functional layer is replaced by an epithelial monolayer which is nonresponsive to hormonal stimulation and fibrous synechiae forms across the cavity. [12] Adhesions involve different layers of endometrium, myometrium or connective tissue.

Treatment of choice of AS is hysteroscopic adhesiolysis followed by prevention of recurrence of adhesions after surgery. This can be done by IUCD insertion, Foley's balloon catheter, hyaluronic acid application or estrogen therapy, with varying results. [13],[14],[15] It has been reported that the recurrence rate for intrauterine adhesions (IUAs) ranges from 3.1% to 23.5% [13],[14],[15] among all cases of IUAs and 20-62.5% [13],[14],[15],[16] in those with severe adhesions.

Patients with recurrence of adhesions or those not responding to the available treatment options are at a disadvantage and have to go for surrogacy or adoption.

Stem cells have long been used successfully to treat several hematopoietic disorders and malignancies such as multiple myeloma, leukemia, and lymphomas. [17]

There is ample evidence that adult stem cell populations exist in human endometrium, and hence it might be possible to activate endogenous endometrial stem/progenitor cells can in cases of atrophic or thin endometrium or to transplant bone marrow (BM) derived stem cells in the uterine cavity for endometrial regeneration in AS or severe cases of IUAs. [18] Low levels of circulating BM derived hemopoietic stem cells, mesenchymal stem cell and endothelial progenitor cells integrate into damaged tissues and trans-differentiate into host tissues, including endometrium. [19],[20] Studies have shown that these cells incorporate into the endometrium in low numbers and trans-differentiate into endometrial epithelial, stromal and endothelial cells. [17],[21],[22],[23]

Implanting autologous hemopoietic adult stem cells into the sub-endometrial zone (junction between myometrium and endometrium) with the opinion that implanted stem cells may trans-differentiate into the resident endometrial stem cells and result in endometrial regeneration, is a novel but promising approach.

The objective of this study was to evaluate the role of sub-endometrial autologous stem cell implantation in regeneration of the endometrium and attaining menstruation. This treatment would provide a new ray of hope for women with AS.

   Materials and Methods Top

The study was conducted for a period of 1 year.

The study was carried out on women of reproductive age between 25 and 35 years with primary or secondary infertility due to AS Grade III or IV (due to any cause), diagnosed hysteroscopically with hypomenorrhea/amenorrhea and in whom standard treatment option of hysteroscopic adhesiolysis followed by estrogen stimulation had failed.

Women with mild degree of IUA, active genital TB, chronic debilitating or hematopoietic diseases affecting the BM and those not willing to participate were excluded from the study.

An informed written consent was obtained from each participant after counseling and explaining the procedure in detail.

These women were a highly selective group, as only after they had failed hysteroscopic adhesiolysis and oral estrogen therapy in the past, were included in the study, hence acted as internal control group.

After history taking and examination to rule out other co-morbidities, a fresh sex hormone profile was done to rule out other causes of amenorrhea before stem cell implantation. This was followed by BM aspiration under local anesthesia in hematology day care center.

Under strict aseptic precaution, BM (30 ml) was aspirated from iliac crest using disposable BM aspiration needle (Jamshidi, 11 G) and collected in heparinized syringes. Samples were immediately transported to stem cell facility, All India Institute of Medical Sciences in sterile plastic tubes for adult stem cell harvesting.

Preparation of hematopoietic stem cell

The isolation of mononuclear cells (MNCs) was done by Ficoll density separation method. BM was diluted in 1:3 ratio with ×1 phosphate buffered saline (PBS) and layered over lymphocyte separation medium and centrifuged at a speed of 800 G for 25 min. [24] MNCs (buffy coat) was aspirated with 10 ml disposable pipette and washed thrice in heparinized normal saline (NS)/PBS to remove the traces of Ficoll. [25] All the procedures were performed in the stem cell laboratory. Finally, MNCs were suspended in 3 ml heparinized NS.

The harvested MNC were evaluated for:

  • Viability: Trypan blue dye exclusion test was done to know the percentage of live cells
  • Cell morphology: MNC were stained with Giemsa stain and observed under microscope
  • CD34 + counts: MNC were tagged with CD34 antibodies and assessed by flow cytometry to evaluate the hematopoietic stem cells [26],[27]
  • Total cell count: Cell numbers were assessed by counting the cell in the Neubauer chamber under microscope.

Same day the patient was taken up for stem cell implantation.

Stem cell implantation

The procedure was conducted in opposing tooth under intravenous (IV) sedation and antibiotic cover (single dose of 1 g cefazolin IV).

Patient was laid in lithotomy position. A transvaginal probe was covered with sterile disposable probe cover and guide attached to it. After locating the sub-endometrial zone on ultrasound (Wipro GE Voluson) ovum pick up needle (Cook No. 17) was introduced vaginally via the lateral fornix and stem cells were implanted in the sub-endometrial zone transmyometrial. A volume of 3 ml of MNC were delivered at 2-3 sites (fundus, anterior and posterior part) of the myometrium.

Patient was discharged after 2 h and antibiotic were given, tablet taxim-O (cefexime, alkem pharma) 200 mg twice a day, for 5 days.

Postprocedure, patients were started on oral estradiol valerate (Progynova, Schering manufacturer), tablets 6 mg/day in three divided doses, the same day for 12 weeks and medroxy progesterone was given in the last 10 days.

Subjects were followed-up at 3, 6, and 9 months interval and were asked to maintain a menstrual calendar. At the follow-up, initiation and changes in menstrual blood flow and their endometrial thickness (ET) between 14 and 18 day by transvaginal ultrasound (TVS) was noted.

Women who were previously amenorrhoeic started having cyclical bleeding after the procedure, this was taken as a sign of endometrial regeneration and was further confirmed by TVS.

Patients who started menstruation were shifted to cyclical oral estrogen (estradiol valerate) 2 mg thrice daily for 21 days (day 1 to day 26) and oral progesterone (Medroxyprogesterone, Serum Institute of India Ltd., India) 10 mg once daily from (day 16 to day 25).

Ethical clearance

The study was approved by the Institutional Committee for Stem Cell Research and Therapy and Human Ethics Committee of the concerned institute. The procedure used in the study was in accordance with guidelines of the Helsinki Declaration of 2000 on human experimentation.

The trial was registered with CTRI - CTRI/2013/08/003896.

Statistical analysis

Though the sample size of this study was small; descriptive statistics and statistical analysis of study variables was carried out using STATA version 9.0.

Changes in ET values due to treatment were compared using paired t-test to see the significant increase in ET values at 3, 6 and 9 months. Bi-variate correlation coefficient between MNC count and CD34 + cell was computed. For all the statistical tests P < 0.05 was considered for statistical significance.

   Results Top

A total of six women were included in the study and all of them had secondary amenorrhea with primary infertility. All of them had undergone hysteroscopic adhesiolysis (2-3 times) and received oral estrogens (2-3 cycles) in the past, but had failed to respond.

The mean age (years) of the study subjects were 29.8 ± 3.37 and all were in the reproductive age group with a mean body mass index (kg/m 2 ) of 24.4 ± 2.24. The mean duration of amenorrhea was of 91.3 ± 115.35 months. Five out of six patients had a past history of genital TB (treated) and one had a history of D and C prior to the onset of amenorrhea [Table 1].
Table 1: Base line characteristics of the study subjects (n=6)

Click here to view

The mean (±standard deviation [SD]) of MNC counts was 103.3 × 10 6 (±20.45) and ranged from 76 × 10 6 to 128 × 10 6 . Similarly the mean (±SD) of CD34 + cells among the MNC's was 203,642 (±269,274) and ranged between 10,640 and 640,090 with a median value 58,800. The average percentage of CD4 positive cells in the MNCs was 0.197% [Table 2].
Table 2: Correlation of ET with CD34 count

Click here to view

The mean preimplantation ET (mm) was 1.38 ± 0.39 and there was a statistically significant increase (t = 4.28, P = 0.008) in the growth of the endometrium to 4.05 ± 1.40 mm at 3 months [Figure 1],[Figure 2] and [Figure 3]. Although the maximum ET attained by any patient was 6.7 mm, the growth of endometrium was found to be static during 6 months (5.46 ± 1.36; t = 8.15; P = 0.001) and 9 months (5.48 ± 1.14; t = 7.40; P = 0.002) follow-up [Table 2].
Figure 1: Endometrial growth over 9 months follow-up

Click here to view
Figure 2: Pretransplant endometrial thickness of one patient

Click here to view
Figure 3: Posttransplant endometrial thickness of the same patient

Click here to view

The correlation between the number of MNC count or CD34 positive cells with the increase in the ET was not significant (P > 0.05) [Table 2].

Five women started menstruating at 3 months posttransplant and continued having cyclical bleeding until 9 months follow-up. One woman who had resumed menses, lost to follow-up after 3 months. Three women had a loss of appetite, mild symptoms of gastritis, abdominal cramps, vomiting at the beginning of the estrogen intake, which resolved subsequently.

   Discussion Top

In this pilot study, six women with severe AS with secondary amenorrhea and infertility who had failed to respond to the standard treatment of hysteroscopic adhesiolysis followed by estrogen therapy were recruited as study subjects. The only case report published so far on this novel therapy is by Nagori et al. [28] Based on this case report and various reports supporting the presence of resident endometrial stem or progenitor cells in the endometrium, which can be activated and the possibility of transplanting BM derived stem cells into the uterine cavity for regeneration, prompted us to perform this study.

In our study, MNCs (3 ml) containing CD34 + cells were implanted in the sub-endometrial zone rather than the uterine cavity. Also it was not preceded by any curettage. Five out of six patients resumed menstruation after 3 months. Though the mean ET postimplantation had significantly increased and the cases were desirous of conception, it was not enough to begin IVF treatment. The maximum ET achieved by any patient was 6.7 mm. Majority of the patients had a past history of treated genital tuberculosis (n = 5) and only one had a history of D and C. The patient selected in their case by Nagori et al. had primary infertility with hypomenorrhea possibly due to previous curettage and premature ovarian failure, indicating that she was not a classical case of infertility due to AS. [28] This is the 1 st time where adult stem transplant has been tried in patients of Asherman's due to genital TB. We do not know whether the inadequate growth of endometrium seen on our study is due to past endometrial TB or whether the results would have been better in patients with traumatic AS. Though, the only patient with history of D and C in the past did not show any difference in the results.

The regeneration seen in our patients could be due to the incorporated cells trans-differentiating into endometrial epithelium and stroma or the BM cells activating the remaining resident endometrial progenitor cells by providing growth factors, to proliferate and replace the lost cells. Further, exogenous oral estrogen given might have promoted the proliferation of a repaired receptive endometrium.

We chose CD34 + marker as they are the endothelial progenitor cells that promotes angiogenesis and tissue repair. Studies in the past have contemplated the mechanism of action of transplanted BM MNCs, CD34 + as being the secretion of certain bioactive molecules that promote angiogenesis and tissue repair, inhibit scarring, modulate inflammatory and immune reactions and activate specific progenitor cells. [29],[30] Though CD34 + cells were quantified, all the MNCs were transplanted and hence which cell type got implanted cannot be commented on.

Taylor detected donor derived endometrial cells in the endometrial biopsy samples of the BM recipients and concluded that BM is the most likely candidate as a potential source of endometrial epithelial and stromal cells. [17] Furthermore, Blau et al. in 2001 found that BM stem cells circulate, albeit in low numbers and populate various organs including uterine endometrium. [31]

The potential role of endometrial injury in provoking endometrial regeneration and its favorable effect on implantation has been studied by various investigators. [32],[33] Furthermore, BM derived stem cells participate in endometrial regeneration in the setting of cellular turnover and inflammatory stimuli. [17] The fact that we did not precede stem cell implantation with endometrial injury might have resulted in not so encouraging results, as far as fertility is concerned. Nagori et al. combined curettage with intrauterine BM transplant and ultrasound monitoring, which resulted in a successful IVF pregnancy. However, this innovative therapy holds promise for many women who have completed their families and suffer from secondary amenorrhea due to Asherman's/IUA. The limitation of our study was the small sample size. This was a pilot study and we plan to do a larger study where more number of patients will be recruited and specific marker positive stem cells will be separated and transplanted, which will enlighten us further. A well-designed large trial is the need of the hour to substantiate the role of this novel therapy in helping these patients resume menses and more importantly conceive.

   Conclusion Top

Autologous stem cell implantation is an innovative therapy for endometrial regeneration in patients with AS. The fact that women resumed menstruation after implantation in our study holds promise for future fertility in patients with infertility due to this dreaded condition.

   References Top

1.Schenker JG, Margalioth EJ. Intrauterine adhesions: An updated appraisal. Fertil Steril 1982;37:593-610.  Back to cited text no. 1
2.Yu D, Wong YM, Cheong Y, Xia E, Li TC. Asherman syndrome - one century later. Fertil Steril 2008;89:759-79.  Back to cited text no. 2
3.Panayiotides I, Weyers S, Bosteels J, Van Herendae B. Intrauterine adhesion (IUA): Has there been progress in understanding and treatment over last 20 years? Gynecol Surg 2009;6:197-211.  Back to cited text no. 3
4.Westendorp IC, Ankum WM, Mol BW, Vonk J. Prevalence of Asherman′s syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion. Hum Reprod 1998;13:3347-50.  Back to cited text no. 4
5.Rochet Y, Dargent D, Bremond A. The obetetrical outcome of women with surgically treated uterine synechiae. J Gynecol Obstet Biol Reprod 1979;8:723-6.  Back to cited text no. 5
6.Parent B, Barbot J, Dubuisson J. Uterine synechiae. Encycl Med Chir Gynecol 1988;140A Suppl:10-2.  Back to cited text no. 6
7.Dmowski WP, Greenblatt RB. Asherman′s syndrome and risk of placenta accreta. Obstet Gynecol 1969;34:288-99.  Back to cited text no. 7
8.Kodaman PH, Arici A. Intra-uterine adhesions and fertility outcome: How to optimize success? Curr Opin Obstet Gynecol 2007;19:207-14.  Back to cited text no. 8
9.Rabau E, David A. Intrauterine adhesions: Etiology, prevention, and treatment. Obstet Gynecol 1963;22:626-9.  Back to cited text no. 9
10.Toaff R, Ballas S. Traumatic hypomenorrhea-amenorrhea (Asherman′s syndrome). Fertil Steril 1978;30:379-87.  Back to cited text no. 10
11.Ventolini G, Zhang M, Gruber J. Hysteroscopy in the evaluation of patients with recurrent pregnancy loss: A cohort study in a primary care population. Surg Endosc 2004;18:1782-4.  Back to cited text no. 11
12.Foix A, Bruno RO, Davison T, Lema B. The pathology of postcurettage intrauterine adhesions. Am J Obstet Gynecol 1966;96:1027-33.  Back to cited text no. 12
13.Valle RF, Sciarra JJ. Intrauterine adhesions: Hysteroscopic diagnosis, classification, treatment, and reproductive outcome. Am J Obstet Gynecol 1988;158:1459-70.  Back to cited text no. 13
14.Pabuçcu R, Atay V, Orhon E, Urman B, Ergün A. Hysteroscopic treatment of intrauterine adhesions is safe and effective in the restoration of normal menstruation and fertility. Fertil Steril 1997;68:1141-3.  Back to cited text no. 14
15.Preutthipan S, Linasmita V. Reproductive outcome following hysteroscopic lysis of intrauterine adhesions: A result of 65 cases at Ramathibodi Hospital. J Med Assoc Thai 2000;83:42-6.  Back to cited text no. 15
16.Capella-Allouc S, Morsad F, Rongières-Bertrand C, Taylor S, Fernandez H. Hysteroscopic treatment of severe Asherman′s syndrome and subsequent fertility. Hum Reprod 1999;14:1230-3.  Back to cited text no. 16
17.Taylor HS. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA 2004;292:81-5.  Back to cited text no. 17
18.Gargett CE, Ye L. Endometrial reconstruction from stem cells. Fertil Steril 2012;98:11-20.  Back to cited text no. 18
19.Kørbling M, Estrov Z. Adult stem cells for tissue repair-a new therapeutic concept? N Engl J Med 2003;349:570-82.  Back to cited text no. 19
20.Du H, Taylor HS. Stem cells and reproduction. Curr Opin Obstet Gynecol 2010;22:235-41.  Back to cited text no. 20
21.Ikoma T, Kyo S, Maida Y, Ozaki S, Takakura M, Nakao S, et al. Bone marrow-derived cells from male donors can compose endometrial glands in female transplant recipients. Am J Obstet Gynecol 2009;201:608.e1-8.  Back to cited text no. 21
22.Mints M, Jansson M, Sadeghi B, Westgren M, Uzunel M, Hassan M, et al. Endometrial endothelial cells are derived from donor stem cells in a bone marrow transplant recipient. Hum Reprod 2008;23:139-43.  Back to cited text no. 22
23.Cervelló I, Gil-Sanchis C, Mas A, Faus A, Sanz J, Moscardó F, et al. Bone marrow-derived cells from male donors do not contribute to the endometrial side population of the recipient. PLoS One 2012;7:e30260.  Back to cited text no. 23
24.Neagu M, Sicui E, Ordodi V, Paunescu V. Human mesenchymal stem cell as basic tools for tissue engineering: Isolation and culture. Rom J Biophys 2012;15:29-34.  Back to cited text no. 24
25.Gilmore MJ, Prentice HG, Blacklock HA, Janossy G, Hoffbrand AV. A technique for rapid isolation of bone marrow mononuclear cells using Ficoll-Metrizoate and the IBM 2991 blood cell processor. Br J Haematol 1982;50:619-26.  Back to cited text no. 25
26.Gajkowska A, Oldak T, Jastrzewska M, Machaj EK, Walewski J, Kraszewska E, et al. Flow cytometric enumeration of CD34 + hematopoietic stem and progenitor cells in leukapheresis product and bone marrow for clinical transplantation: A comparison of three methods. Folia Histochem Cytobiol 2006;44:53-60.  Back to cited text no. 26
27.Mackie AR, Losordo DW. CD34-positive stem cells: In the treatment of heart and vascular disease in human beings. Tex Heart Inst J 2011;38:474-85.  Back to cited text no. 27
28.Nagori B, Panchal S, Patel H. Endometrial regeneration using autologous adult stem cell followed by conception by in vitro fertilization in a patients of severe Asherman′s syndrome. J Hum Reprod Sci 2011;4:43-8.  Back to cited text no. 28
[PUBMED]  Medknow Journal  
29.Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther 2009;17:939-46.  Back to cited text no. 29
30.Caplan AI. Why are MSCs therapeutic? New data: New insight. J Pathol 2009;217:318-24.  Back to cited text no. 30
31.Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: Entity or function? Cell 2001;105:829-41.  Back to cited text no. 31
32.Barash A, Dekel N, Fieldust S, Segal I, Schechtman E, Granot I. Local injury to the endometrium doubles the incidence of successful pregnancies in patients undergoing in vitro fertilization. Fertil Steril 2003;79:1317-22.  Back to cited text no. 32
33.Li R, Hao G. Local injury to the endometrium: Its effect on implantation. Curr Opin Obstet Gynecol 2009;21:236-9.  Back to cited text no. 33


  [Figure 1], [Figure 2], [Figure 3]

  [Table 1], [Table 2]

This article has been cited by
1 Cell-based therapy in thin endometrium and Asherman syndrome
Nastaran Gharibeh, Leili Aghebati-Maleki, Javad Madani, Ramin Pourakbari, Mehdi Yousefi, Javad Ahmadian Heris
Stem Cell Research & Therapy. 2022; 13(1)
[Pubmed] | [DOI]
2 Treating intrauterine adhesion using conditionally reprogrammed physiological endometrial epithelial cells
Siyu Xia, Ming Wu, Xinhao Zhou, Xiu Zhang, Lina Ye, Kang Zhang, Yiyi Kang, Jun Liu, Yunci Zhang, Wang Wu, Dirong Dong, Hong Chen, Hui Li
Stem Cell Research & Therapy. 2022; 13(1)
[Pubmed] | [DOI]
3 Metabolic Rewiring by Human Placenta-Derived Mesenchymal Stem Cell Therapy Promotes Rejuvenation in Aged Female Rats
Kyeoung-Hwa Kim, Kyung-Ah Lee
International Journal of Molecular Sciences. 2022; 23(1): 566
[Pubmed] | [DOI]
4 The Role of Endometrial Stem/Progenitor Cells in Recurrent Reproductive Failure
Hannan Al-Lamee, Christopher J. Hill, Florence Turner, Thuan Phan, Andrew J. Drakeley, Dharani K. Hapangama, Nicola Tempest
Journal of Personalized Medicine. 2022; 12(5): 775
[Pubmed] | [DOI]
5 Successful application of combined autologous bone marrow-derived stem cells and platelet-rich plasma in a case of severe asherman syndrome and subsequent in vitro fertilization conception
Sunita Tandulwadkar, Sneha Mishra, Shruti Gupta
Journal of Human Reproductive Sciences. 2021; 14(4): 446
[Pubmed] | [DOI]
6 Birth of a healthy infant after bone marrow-derived cell therapy
Nayana H Patel, Yuvraj D Jadeja, Niket H Patel, Molina N Patel, Harsha K Bhadarka, Piyush N Chudasama, Harmi R Thakkar
Clinical and Experimental Reproductive Medicine. 2021; 48(3): 268
[Pubmed] | [DOI]
7 Making More Womb: Clinical Perspectives Supporting the Development and Utilization of Mesenchymal Stem Cell Therapy for Endometrial Regeneration and Infertility
Michael Strug, Lusine Aghajanova
Journal of Personalized Medicine. 2021; 11(12): 1364
[Pubmed] | [DOI]
8 The Latest Developments in Immunomodulation of Mesenchymal Stem Cells in the Treatment of Intrauterine Adhesions, Both Allogeneic and Autologous
Jia-ming Chen, Qiao-yi Huang, Yun-xia Zhao, Wei-hong Chen, Shu Lin, Qi-yang Shi
Frontiers in Immunology. 2021; 12
[Pubmed] | [DOI]
9 Application of Stem Cell Therapy for Infertility
Sarama Saha, Partha Roy, Cynthia Corbitt, Sham S. Kakar
Cells. 2021; 10(7): 1613
[Pubmed] | [DOI]
10 The Role of Stem Cells and Their Derived Extracellular Vesicles in Restoring Female and Male Fertility
Ahmad Yar Qamar, Tariq Hussain, Muhammad Kamran Rafique, Seonggyu Bang, Bereket Molla Tanga, Gyeonghwan Seong, Xun Fang, Islam M. Saadeldin, Jongki Cho
Cells. 2021; 10(9): 2460
[Pubmed] | [DOI]
11 Stem Cells and Organs-on-chips: New Promising Technologies for Human Infertility Treatment
Eisa Tahmasbpour Marzouni, Catharyn Stern, Andrew Henrik Sinclair, Elena Jane Tucker
Endocrine Reviews. 2021;
[Pubmed] | [DOI]
12 Stem Cell-Based Therapy for Asherman Syndrome: Promises and Challenges
Yiyin Gao, Guijie Wu, Ying Xu, Donghai Zhao, Lianwen Zheng
Cell Transplantation. 2021; 30: 0963689721
[Pubmed] | [DOI]
13 Effectiveness of electroacupuncture for thin endometrium in infertile women: study protocol for a single-blind, randomized controlled trial
Fangyuan Li, Hua Lu, Xinxin Wang, Qi Zhang, Qianchen Liu, Tong Wang
Trials. 2021; 22(1)
[Pubmed] | [DOI]
14 Unresponsive thin endometrium caused by Asherman syndrome treated with umbilical cord mesenchymal stem cells on collagen scaffolds: a pilot study
Yanling Zhang, Libing Shi, Xiaona Lin, Feng Zhou, Liaobing Xin, Wenzhi Xu, Huaying Yu, Jing Li, Mei Pan, Yibin Pan, Yongdong Dai, Yinli Zhang, Jia Shen, Lijuan Zhao, Min Lu, Songying Zhang
Stem Cell Research & Therapy. 2021; 12(1)
[Pubmed] | [DOI]
15 3D stem cell-laden artificial endometrium: successful endometrial regeneration and pregnancy
Se-Ra Park, Soo-Rim Kim, Jae Been Im, Chan Hum Park, Hwa-Yong Lee, In-Sun Hong
Biofabrication. 2021; 13(4): 045012
[Pubmed] | [DOI]
16 Novel microarchitecture of human endometrial glands: implications in endometrial regeneration and pathologies
Nicola Tempest, Christopher J Hill, Alison Maclean, Kathleen Marston, Simon G Powell, Hannan Al-Lamee, Dharani K Hapangama
Human Reproduction Update. 2021;
[Pubmed] | [DOI]
17 Endometrial stem cells: origin, biological function, and therapeutic applications for reproductive disorders
Nafeesa Abuwala, Reshef Tal
Current Opinion in Obstetrics & Gynecology. 2021; 33(3): 232
[Pubmed] | [DOI]
18 Strategies for managing Asherman's syndrome and endometrial atrophy: Since the classical experimental models to the new bioengineering approach
Lucía Miguel-Gómez, Mónica Romeu, Antonio Pellicer, Irene Cervelló
Molecular Reproduction and Development. 2021; 88(8): 527
[Pubmed] | [DOI]
19 Uterine Stem Cells and Benign Gynecological Disorders: Role in Pathobiology and Therapeutic Implications
Malak El Sabeh, Sadia Afrin, Bhuchitra Singh, Mariko Miyashita-Ishiwata, Mostafa Borahay
Stem Cell Reviews and Reports. 2021; 17(3): 803
[Pubmed] | [DOI]
20 Is It Possible to Treat Infertility with Stem Cells?
P. Petric, E. Vrtacnik-Bokal, M. Stimpfel
Reproductive Sciences. 2021; 28(6): 1733
[Pubmed] | [DOI]
21 Endometrial membrane organoids from human embryonic stem cell combined with the 3D Matrigel for endometrium regeneration in asherman syndrome
Xiuxiu Jiang, Xingmiao Li, Xiangwei Fei, Jiajie Shen, Jianhua Chen, Meijun Guo, Yangyang Li
Bioactive Materials. 2021; 6(11): 3935
[Pubmed] | [DOI]
22 A comparative evaluation of subendometrial and intrauterine platelet-rich plasma treatment for women with recurrent implantation failure
Majiyd Abdul Noushin, Mohamed Ashraf, Chaitra Thunga, Sankalp Singh, Swati Singh, Reema Basheer, Raiza Ashraf, Kanna Jayaprakasan
F&S Science. 2021; 2(3): 295
[Pubmed] | [DOI]
23 Sonic Hedgehog, a Novel Endogenous Damage Signal, Activates Multiple Beneficial Functions of Human Endometrial Stem Cells
Se-Ra Park, Soo-Rim Kim, Chan Hum Park, Soyi Lim, Seung Yeon Ha, In-Sun Hong, Hwa-Yong Lee
Molecular Therapy. 2020; 28(2): 452
[Pubmed] | [DOI]
24 Perivascular Stem Cell-Derived Cyclophilin A Improves Uterine Environment with Asherman’s Syndrome via HIF1a-Dependent Angiogenesis
Mira Park, Seok-Ho Hong, So Hee Park, Yeon Sun Kim, Seung Chel Yang, Hye-Ryun Kim, Songmi Noh, Sunghun Na, Hyung Keun Lee, Hyunjung J. Lim, Sang Woo Lyu, Haengseok Song
Molecular Therapy. 2020; 28(8): 1818
[Pubmed] | [DOI]
25 Tryptophanyl-tRNA Synthetase, a Novel Damage-Induced Cytokine, Significantly Increases the Therapeutic Effects of Endometrial Stem Cells
Se-Ra Park, Soo-Rim Kim, Jae-Been Im, Soyi Lim, In-Sun Hong
Molecular Therapy. 2020; 28(11): 2458
[Pubmed] | [DOI]
26 Endometrial autotransplantation in rabbits: Potential for fertility restoration in severe Asherman’s syndrome
Benjamin P. Jones, Saaliha Vali, Srdjan Saso, Ximo Garcia-Dominguez, Maxine Chan, Meen-Yau Thum, Sadaf Ghaem-Maghami, Baljeet Kaur, Luís García-Valero, Linda Petrucci, Joseph Yazbek, Jose S. Vicente, Isabel Quiroga, Francisco Marco-Jiménez, J. Richard Smith
European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020; 248: 14
[Pubmed] | [DOI]
27 An update on stem cell therapy for Asherman syndrome
Ariel Benor, Steven Gay, Alan DeCherney
Journal of Assisted Reproduction and Genetics. 2020; 37(7): 1511
[Pubmed] | [DOI]
28 Should we consider alternative therapies to operative hysteroscopy for the treatment of Asherman syndrome?
Xavier Santamaria, James H. Liu, Aghajanova Lusine, Keith Isaacson, Peter Movilla, Hervé Fernandez, Perrine Capmas, Jacques Donnez, Carlos Simón
Fertility and Sterility. 2020; 113(3): 511
[Pubmed] | [DOI]
29 Menstruation: science and society
Hilary O.D. Critchley, Elnur Babayev, Serdar E. Bulun, Sandy Clark, Iolanda Garcia-Grau, Peter K. Gregersen, Aoife Kilcoyne, Ji-Yong Julie Kim, Missy Lavender, Erica E. Marsh, Kristen A. Matteson, Jacqueline A. Maybin, Christine N. Metz, Inmaculada Moreno, Kami Silk, Marni Sommer, Carlos Simon, Ridhi Tariyal, Hugh S. Taylor, Günter P. Wagner, Linda G. Griffith
American Journal of Obstetrics and Gynecology. 2020; 223(5): 624
[Pubmed] | [DOI]
30 Effect of Autologous Adipose-Derived Stromal Vascular Fraction Transplantation on Endometrial Regeneration in Patients of Asherman’s Syndrome: a Pilot Study
Se Yun Lee, Ji Eun Shin, Hwang Kwon, Dong Hee Choi, Ji Hyang Kim
Reproductive Sciences. 2020; 27(2): 561
[Pubmed] | [DOI]
31 Transforming growth factor-ß1 in intrauterine adhesion
Ayitila Abudukeyoumu, Ming-Qing Li, Feng Xie
American Journal of Reproductive Immunology. 2020; 84(2)
[Pubmed] | [DOI]
32 Intrauterine transplantation of autologous menstrual blood stem cells increases endometrial thickness and pregnancy potential in patients with refractory intrauterine adhesion
Hailan Ma, Mengting Liu, Yufeng Li, Wei Wang, Keqin Yang, Lanying Lu, Mei He, Taoran Deng, Meiling Li, Dongcheng Wu
Journal of Obstetrics and Gynaecology Research. 2020; 46(11): 2347
[Pubmed] | [DOI]
33 In situ repair abilities of human umbilical cord–derived mesenchymal stem cells and autocrosslinked hyaluronic acid gel complex in rhesus monkeys with intrauterine adhesion
Lingjuan Wang, Chuanhu Yu, Tianli Chang, Mengdi Zhang, Su Song, Chengliang Xiong, Pin Su, Wenpei Xiang
Science Advances. 2020; 6(21)
[Pubmed] | [DOI]
34 Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis
Yiming Zhao, Qifan Luo, Xiao Zhang, Yafei Qin, Jingpeng Hao, Dejun Kong, Hongda Wang, Guangming Li, Xiangying Gu, Hao Wang, Mahmood S. Choudhery
Stem Cells International. 2020; 2020: 1
[Pubmed] | [DOI]
35 Preventive Effects of Intrauterine Injection of Bone Marrow-Derived Mesenchymal Stromal Cell-Conditioned Media on Uterine Fibrosis Immediately after Endometrial Curettage in Rabbit
Sanaz Bazoobandi, Nader Tanideh, Farhad Rahmanifar, Shahrokh Zare, Omid Koohi-Hosseinabadi, Iman Razeghian-Jahromi, Mehdi Dianatpour, Masoumeh Ahmadi, Arezoo Khoradmehr, Iraj Nabipour, Zahra Khodabandeh, Amin Tamadon, Patricia Murray
Stem Cells International. 2020; 2020: 1
[Pubmed] | [DOI]
36 Therapeutic Effect of Human Amniotic Epithelial Cells in Rat Models of Intrauterine Adhesions
Xuechai Bai, Jia Liu, Weixin Yuan, Yang Liu, Wei Li, Siyu Cao, Luyang Yu, Liang Wang
Cell Transplantation. 2020; 29: 0963689720
[Pubmed] | [DOI]
37 Organoid technology in female reproductive biomedicine
Heidar Heidari-Khoei, Fereshteh Esfandiari, Mohammad Amin Hajari, Zeynab Ghorbaninejad, Abbas Piryaei, Hossein Baharvand
Reproductive Biology and Endocrinology. 2020; 18(1)
[Pubmed] | [DOI]
38 Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility
Sahar Esfandyari, Rishi Man Chugh, Hang-soo Park, Elie Hobeika, Mara Ulin, Ayman Al-Hendy
Cells. 2020; 9(10): 2253
[Pubmed] | [DOI]
39 Mini-Review of the New Therapeutic Possibilities in Asherman Syndrome—Where Are We after One Hundred and Twenty-Six Years?
Bogdan Doroftei, Ana-Maria Dabuleanu, Ovidiu-Dumitru Ilie, Radu Maftei, Emil Anton, Gabriela Simionescu, Theodor Matei, Theodora Armeanu
Diagnostics. 2020; 10(9): 706
[Pubmed] | [DOI]
40 Adipose tissue-derived regenerative cells improve implantation of fertilized eggs in thin endometrium
Fusanori Yotsumoto, Hideki Iwaguro, Yusuke Harada, Satoshi Sobajima, Takako Suwabe, Shingo Miyamoto
Regenerative Medicine. 2020; 15(7): 1891
[Pubmed] | [DOI]
41 Autologous bone marrow-derived stem cell therapy for Asherman's syndrome and endometrial atrophy: A 5-year follow-up study
Neeta Singh, Bhawani Shekhar, Sujata Mohanty, Sunesh Kumar, Tulika Seth, Bhavana Girish
Journal of Human Reproductive Sciences. 2020; 13(1): 31
[Pubmed] | [DOI]
42 Safety of menstrual blood-derived stromal cell transplantation in treatment of intrauterine adhesion
Qi-Yuan Chang, Si-Wen Zhang, Ping-Ping Li, Zheng-Wei Yuan, Ji-Chun Tan
World Journal of Stem Cells. 2020; 12(5): 368
[Pubmed] | [DOI]
43 Current status of uterine regenerative medicine for absolute uterine factor infertility (Review)
Yusuke Matoba, Iori Kisu, Asako Sera, Megumi Yanokura, Kouji Banno, Daisuke Aoki
Biomedical Reports. 2019;
[Pubmed] | [DOI]
44 Role of Stem Cells in the Future of Asherman Syndrome Treatment
M. Mahmoodinia, M. Roustaie
Sarem Journal of Reproductive Medicine. 2019; 4(2): 87
[Pubmed] | [DOI]
45 Bone Marrow Stem Cells Do Not Contribute to Endometrial Cell Lineages in Chimeric Mouse Models
Yih Rue Ong, Fiona L. Cousins, Xiaoqing Yang, Ahmed Aedh A. Al Mushafi, David T. Breault, Caroline E. Gargett, James A. Deane
STEM CELLS. 2018; 36(1): 91
[Pubmed] | [DOI]
46 Stem cell therapy in Asherman syndrome and thin endometrium: Stem cell- based therapy
Ramyar Azizi, Leili Aghebati-Maleki, Mohammad Nouri, Faroogh Marofi, Sohrab Negargar, Mehdi Yousefi
Biomedicine & Pharmacotherapy. 2018; 102: 333
[Pubmed] | [DOI]
47 Menstrual Stem cells
S Lakhanpal, B Gupta
Journal of Gynecological Research and Obstetrics. 2017; 3(1): 008
[Pubmed] | [DOI]
48 Human CD133+ bone marrow-derived stem cells promote endometrial proliferation in a murine model of Asherman syndrome
Irene Cervelló, Claudia Gil-Sanchis, Xavier Santamaría, Sergio Cabanillas, Ana Díaz, Amparo Faus, Antonio Pellicer, Carlos Simón
Fertility and Sterility. 2015; 104(6): 1552
[Pubmed] | [DOI]


Print this article  Email this article


    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Article in PDF (849 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

    Materials and Me...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded374    
    Comments [Add]    
    Cited by others 48    

Recommend this journal